Morgan Stanley upgraded Fisher & Paykel Healthcare to Overweight from Equal Weight with a price target of NZ$38.90, up from NZ$36.70. The share price has declined by about 4% following the FY25 result, which the firm sees as reflecting weaker than expected FY26 guidance, but it adds that it sees F&P offering attractive medium-long term EPS growth.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FSPKF:
- Fisher & Paykel Healthcare Reports Strong Earnings Growth
- Fisher & Paykel Healthcare upgraded to Buy from Hold at Jefferies
- Fisher & Paykel Healthcare downgraded to Underperform at RBC Capital
- Fisher & Paykel Healthcare Surpasses $2 Billion Revenue Milestone
- Fisher & Paykel Healthcare Announces Dividend Distribution